Arena Pharmaceuticals (NASDAQ:ARNA) rose 7.8% premarket following news that its phase III clinical trial of its lorcaserin obesity drug showed statically significant weight loss among its patients with Type 2 diabetes. That being said, it still may not be sufficient in satisfying requirements in order to get the FDA’s approval, which has been extremely tough on obesity drug applications. On September 17, 2010, Arena Pharmaceuticals (NASDAQ:ARNA) was downgraded to Neutral from Overweight at Piper Jaffray. The stock is trading at .53 which is 23.12% lower than the downgrade price of .99.
美国肥胖率升势趋缓但挑战犹存
Arena的lorcaserin已在2010年被食品和药物管理局否决，原因是使用小白鼠进行研究后的结果表明，这种药物可能存在引发脑瘤的风险。但后续研究表明，这种药物对人脑和鼠脑的影响要小，因此食品和药物管理局已经接受了 …
Read more on 新浪网
